Orion Oyj Class B
EURO STOXX 600Last update: May 9, 2026 at 09:32
Dividend Safety Rating
ORNBV.HE's dividend appears safe and well-supported. Strengths include a 45.7% earnings payout ratio & 77.6x interest coverage. Areas of concern: 122.9% fcf payout ratio & 86.9% cfo payout ratio.
Based on 15 of 15 metrics
Strengths
- Earnings Payout Ratio: 45.7%Low earnings payout ratio leaves room to grow the dividend.
- Interest Coverage: 77.6xEarnings cover interest payments many times over.
- Net Debt / Total Assets: 7.2%Healthy balance sheet with low net debt.
Risks
- FCF Payout Ratio: 122.9%Free cash flow is tight relative to the dividend.
- CFO Payout Ratio: 86.9%Operating cash flow leaves little room for the payout.
- 5-Year Dividend CAGR: 1.8%Dividend growth has been weak or negative.
Payout & Coverage
CautionBalance Sheet
Very SafeProfitability
Very SafeDividend Track Record
SafeAbout Orion Oyj Class B
Orion Oyj Class B represents the publicly traded Class B shares of Orion Oyj, a globally operating Finnish pharmaceutical company founded in 1917 and headquartered in Espoo, Finland. The company develops, manufactures, and markets human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients, with a primary focus on treatments for central nervous system disorders, oncology, respiratory diseases, prostate cancer, Parkinson's disease, asthma, chronic obstructive pulmonary disease, and inflammatory pain. Notable products include Nubeqa for prostate cancer, Stalevo and Comtess for Parkinson's, Easyhaler inhalers for respiratory conditions, and veterinary drugs like Domosedan and Antisedan. Orion Oyj serves specialists, general practitioners, veterinarians, pharmacies, hospitals, and laboratories, with its core market in Finland and additional presence across Europe, North America, and other regions. Employing around 3,989 people, it operates in the pharmaceuticals and biotech sector, contributing to healthcare innovation through proprietary developments, contract manufacturing, and strategic collaborations for antibody therapeutics.
Dividend Overview
Dividend Yield
1.31%
Annual Dividend
€0.90
Frequency
Annual
Payout Ratio
45.74%
FCF Payout Ratio
122.93%
Stock Price
—
52-Week Range
€46.62 – €75.30
Dividend History (2016–2025)
ORNBV.HE annual dividend per share and yield history
Earnings & Profitability
ORNBV.HE earnings per share and net profit margin
Key Dates
Next Ex-Dividend Date
October 19, 2026
Next Payment Date
—
Dividend Growth
3-Year Dividend CAGR
3.02%
5-Year Dividend CAGR
1.80%
10-Year Dividend CAGR
2.35%
3-Year Total Growth
9.33%
5-Year Total Growth
9.33%
10-Year Total Growth
26.15%
Income Calculator
Frequently Asked Questions
What is ORNBV.HE's current dividend yield?
When is ORNBV.HE's next dividend payment date?
How much does ORNBV.HE pay in dividends per year?
Has ORNBV.HE been increasing its dividend?
Is ORNBV.HE's dividend safe?
How is ORNBV.HE's Dividend Safety Rating calculated?
Want to understand how we rate dividend safety? Read our full methodology
Track ORNBV.HE Dividends with OnlyDividends
What will ORNBV.HE actually pay you after taxes? Track every payout, get notified on payment dates, and stop guessing.
This page is not investment advice. The content is for informational purposes only and should not be construed as a recommendation to buy, sell, or hold any security. Always do your own research and consult a qualified financial advisor before making investment decisions.
Financial data, including dividend history, earnings, balance sheet metrics, and the Dividend Safety Rating, is provided for informational purposes only. Data may be delayed or differ from official filings. Past performance does not guarantee future results. Always verify with official sources before making investment decisions.
Market data provided by Twelve Data.